These data demonstrate the ability for erlotinib and afatinib to block downstream signalling pathway, inhibit proliferation and induce cell cycle arrest and apoptosis in selected EGFR-amplified ESCC cell lines. Here, EGFR is linked to esophageal squamous cell carcinoma.